We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis.
- Authors
Spelman, T.; Mekhael, L.; Burke, T.; Butzkueven, H.; Hodgkinson, S.; Havrdova, E.; Horakova, D.; Duquette, P.; Izquierdo, G.; Grand'Maison, F.; Grammond, P.; Barnett, M.; Lechner ‐ Scott, J.; Alroughani, R.; Trojano, M.; Lugaresi, A.; Granella, F.; Pucci, E.; Vucic, S.
- Abstract
Background and Purpose Early relapse outcomes in long-term stable patients switching from interferon β/glatiramer acetate ( IFNβ/ GA) to oral therapy are unknown. Objective The objective of this study was to compare early relapse and progression in multiple sclerosis ( MS) patients switching to oral therapy following a period of stable disease on IFNβ/ GA, relative to a propensity-matched comparator of patients remaining on IFNβ/ GA. Methods The MSBase cohort study is a global, longitudinal registry for MS. Time to first 6-month relapse in previously stable MS patients switching from platform injectables ('switchers') to oral agents were compared with propensity-matched patients remaining on IFNβ/ GA ('stayers') using a Cox marginal model. Results Three-hundred and ninety-six switchers were successfully matched to 396 stayers on a 1:1 basis. There was no difference in the proportion of patients recording at least one relapse in the first 1−6 months by treatment arm (7.3% switchers, 6.6% stayers; P = 0.675). The mean annualized relapse rate ( P = 0.493) and the rate of first 6-month relapse by treatment arm (hazard ratio 1.22, 95% confidence interval 0.70, 2.11) were also comparable. There was no difference in the rate of disability progression by treatment arm (hazard ratio 1.43, 95% confidence interval 0.63, 3.26). Conclusion This is the first study to compare early relapse switch probability in the period immediately following switch to oral treatment in a population previously stable on injectable therapy. There was no evidence of disease reactivation within the first 6 months of switching to oral therapy.
- Subjects
MULTIPLE sclerosis treatment; INTERFERONS; PATIENTS; DEMYELINATION; DISEASE relapse
- Publication
European Journal of Neurology, 2016, Vol 23, Issue 4, p729
- ISSN
1351-5101
- Publication type
Article
- DOI
10.1111/ene.12929